Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 9/20 | 0.45 |
| ▸ | AURKA | O14965 | 6/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | ESRRG | P62508 | 2/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965317 | 1.00 | MAPK7 (0.45) | MAPK7AURKAHRH3ESR1ESRRG | |
| SCHEMBL5137699 | 0.96 | AURKA (0.49) | MAPK7AURKAHRH3AURKB | |
| SCHEMBL5006918 | 0.96 | AURKA (0.49) | MAPK7AURKAHRH3AURKB | |
| SCHEMBL3568186 | 0.87 | AURKA (0.45) | MAPK7AURKAHRH3ESR1ESRRG | |
| SCHEMBL3568181 | 0.87 | AURKA (0.45) | MAPK7AURKAHRH3ESR1ESRRG | |
| SCHEMBL4963499 | 0.85 | MAPK7 (0.52) | MAPK7 | |
| SCHEMBL12049310 | 0.84 | AURKA (0.45) | AURKAAURKB | |
| SCHEMBL5138448 | 0.84 | MAPK7 (0.49) | MAPK7AURKAHRH3AURKB | |
| SCHEMBL4965011 | 0.84 | MAPK7 (0.52) | MAPK7AURKAAURKB | |
| SCHEMBL4969423 | 0.83 | MAPK7 (0.49) | MAPK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | MAPK7 489/4885AURKA 94/4885HRH3 1117/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | MAPK7 957/4885AURKA 174/4885HRH3 2442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.